Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus

scientific article published on 16 January 2017

Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/SREP40627
P932PMC publication ID5238426
P698PubMed publication ID28091558

P50authorRóbert WagnerQ57119081
Hans-Ulrich HäringQ63256451
Andreas FritscheQ87609923
Elko RandrianarisoaQ87788993
Nils HeyneQ91662869
Martina GuthoffQ91662875
Erifili HatziagelakiQ117216328
P2093author name stringAndreas Peter
P2860cites workA new equation to estimate glomerular filtration rateQ24651973
suPAR: the molecular crystal ballQ28263862
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitusQ30426632
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosisQ33872298
Diabetic nephropathy: diagnosis, prevention, and treatmentQ34379284
Blocking αVβ3 integrin ligand occupancy inhibits the progression of albuminuria in diabetic rats.Q34441673
Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular diseaseQ34787780
Microvascular complications of impaired glucose tolerance.Q35591509
Soluble Urokinase Receptor and Chronic Kidney Disease.Q36429637
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin ActivationQ36987307
A new paradigm to understand and treat diabetic neuropathy.Q38195562
Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetesQ42924246
Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetesQ43511438
Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis studyQ44372241
Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria).Q44717786
The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men.Q51365869
Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.Q51723464
Modification of kidney barrier function by the urokinase receptor.Q53510545
The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body wQ59299925
Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivoQ72344903
Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. The Microalbuminuria Collaborative Study GroupQ73250901
Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up studyQ74181586
Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?Q81402639
The estimation of average hazard ratios by weighted Cox regressionQ83921596
Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathyQ85570577
The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosisQ87055318
A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular diseaseQ87105637
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P921main subjecttype 2 diabetesQ3025883
P304page(s)40627
P577publication date2017-01-16
P1433published inScientific ReportsQ2261792
P1476titleSoluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus
P478volume7

Reverse relations

cites work (P2860)
Q42265982Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation
Q47854753Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children
Q38718670Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors
Q90372112Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease
Q57243215Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood
Q38754939Extrarenal determinants of kidney filter function
Q64097684Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease
Q57189799Mechanisms underlying modulation of podocyte TRPC6 channels by suPAR: Role of NADPH oxidases and Src family tyrosine kinases
Q96577243Senolytic CAR T cells reverse senescence-associated pathologies
Q33741426Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.
Q38685434Unwinding focal segmental glomerulosclerosis
Q39423366suPAR and chronic kidney disease-a podocyte story.